Tag Archives: Debjit Chattopadhyay

Global Blood Therapeutics (GBT) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Global Blood Therapeutics (GBT – Research Report) today and set a price target of $150.00. The company’s shares closed last Monday at $46.46. According to TipRanks.com, Chattopadhyay is currently ranked

Analysts Offer Insights on Healthcare Companies: Homology Medicines Inc (NASDAQ: FIXX) and Taiwan Liposome Company Ltd (NASDAQ: TLC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines Inc (FIXX – Research Report) and Taiwan Liposome Company Ltd (TLC – Research Report) with bullish sentiments. Homology Medicines Inc

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Autolus Therapeutics Plc (NASDAQ: AUTL) and Cryolife (NYSE: CRY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Autolus Therapeutics Plc (AUTL – Research Report) and Cryolife (CRY – Research Report). Autolus Therapeutics Plc (AUTL) H.C. Wainwright analyst Debjit Chattopadhyay maintained

Analysts Are Bullish on Top Healthcare Stocks: uniQure NV (QURE), Kura Oncology (KURA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on uniQure NV (QURE – Research Report) and Kura Oncology (KURA – Research Report) with bullish sentiments. uniQure NV (QURE) In a report

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Nektar Therapeutics (NASDAQ: NKTR), Verrica Pharmaceuticals Inc (NASDAQ: VRCA) and Gritstone Oncology Inc (NASDAQ: GRTS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nektar Therapeutics (NKTR – Research Report), Verrica Pharmaceuticals Inc (VRCA – Research Report) and Gritstone Oncology Inc (GRTS – Research Report). Nektar Therapeutics

Voyager Therapeutics Inc (VYGR) Receives a Buy from H.C. Wainwright

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Voyager Therapeutics Inc (VYGR – Research Report), with a price target of $26. The company’s shares closed on Friday at $20.53. Chattopadhyay noted: “Our current